Interactive Exchange Multidimensional Outcomes in Type 2 Diabetes: Looking Beyond Hemoglobin A1c

1.00 CME
$0 FEE
Interactive Exchange™ Multidimensional Outcomes in Type 2 Diabetes: Looking Beyond Hemoglobin A1c

Program Title
Interactive Exchange Multidimensional Outcomes in Type 2 Diabetes: Looking Beyond Hemoglobin A1c

 Integritas     Global   

This activity is jointly provided by Global Education Group and Integritas Communications.
This activity is supported by an independent educational grant from AstraZeneca.

Launch Date
January 15, 2020

Expiration Date
January 15, 2021

Target Audience

The educational design of this activity addresses the needs of cardiology, endocrinology, and diabetology clinicians involved in the treatment of patients with type 2 diabetes mellitus (T2DM).

Educational Objectives

After completing this activity, the participant should be better able to:

  • Describe the pathophysiologic relationships between T2DM and cardiovascular disease (CVD), heart failure (HF), and chronic kidney disease (CKD), including implications for antihyperglycemic treatment
  • Compare the designs and results of large-scale cardiovascular outcomes trials with sodium-glucose cotransporter-2 (SGLT2) inhibitors for T2DM
  • Discuss the mechanistic profiles, evidence for clinical benefits, and safety concerns associated with SGLT2 inhibitors as treatment options for patients with T2DM
  • Collaborate with other clinicians to treat patients with T2DM based on cardiovascular and renal risks, recent guideline recommendations, and other clinical parameters

Program Overview

Diabetes disorders afflict more than 30 million Americans, while another 84 million adult Americans have prediabetes.1 Multisystem consequences of T2DM include CVD, HF, and CKD. The pathophysiologic mechanisms underlying T2DM, CVD, HF, and CKD share common characteristics: metabolic changes, a proinflammatory state, and oxidative stress.2 Following several cardiovascular outcomes clinical trials with SGLT2 inhibitors, the American Diabetes Association recommends incorporating these agents (and other antihyperglycemic classes, such as glucagon-like peptide-1 receptor agonists), into treatment regimens for T2DM, particularly when CVD risks are elevated.3 The established relationships among T2DM, CVD, HF, and CKD necessitate individualized treatment to avoid or mitigate hyperglycemia and these common comorbidities. Cardiologists, in particular, must be knowledgeable about how updates to guidelines outside of the cardiology space have evolved, allowing them to contribute to multidisciplinary best-practices for the treatment of patients with T2DM and common comorbidities. This enduring Interactive Exchange program will address these topics to ensure attendees understand the role of maladaptive glucose reabsorption in T2DM, the benefits SGLT2 inhibitors may have on common comorbidities associated with T2DM, and the role the cardiologist plays in diabetes management.


1. Centers for Disease Control and Prevention. National diabetes statistics report. 2017; Accessed November 15, 2018.
2. Kovacic JC, Castellano JM, Farkouh ME, Fuster V. The relationships between cardiovascular disease and diabetes: focus on pathogenesis. Endocrinol Metab Clin North Am. 2014;43(1):41-57.
3. American Diabetes Association. Standard of Medical Care in Diabetes – 2019. Diabetes Care. 2019;42(suppl 1):S1-S193.


Christopher P. Cannon, MD
Education Director, Cardiovascular Innovation
Preventive Cardiology Section
Brigham and Women’s Hospital
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Dr. Christopher Cannon is a Professor of Medicine at Harvard Medical School, and senior physician in the Cardiovascular Division at Brigham and Women’s Hospital. Education Director in the Cardiovascular Innovation group, he has worked for 25 years as an investigator in the TIMI Study Group and for 5 years with the Harvard Clinical Research Institute (now Baim Institute). He earned his medical degree from Columbia University College of Physicians and Surgeons in New York and did internal medicine residency at Columbia Presbyterian Medical Center and cardiovascular fellowship at Brigham and Women’s Hospital.

Dr. Cannon has published over 1000 original articles, reviews, or book chapters on acute coronary syndromes and their prevention and has authored or edited 18 books. He has received numerous awards, including leadership awards from the American College of Cardiology, American Heart Association, and National Lipid Association.

He has been principal investigator of more than 20 multicenter clinical trials, including TACTICS-TIMI 18, PROVE IT, IMPROVE IT, and RE-DUAL PCI trials. He is currently working on clinical trials, registries, and quality improvement projects in the fields of acute coronary syndromes, atrial fibrillation, diabetes, lipids, and prevention. In his new role at Brigham Cardiovascular Medicine Innovation, he aims to help develop and implement quality improvement programs, including pragmatic clinical trials, into new care delivery systems.

Serge A. Jabbour, MD, FACP, FACE
Professor of Medicine
Director, Division of Endocrinology, Diabetes and Metabolic Diseases
Sidney Kimmel Medical College
Thomas Jefferson University
Philadelphia, Pennsylvania

Dr. Serge Jabbour is Professor of Medicine and Director of the Division of Endocrinology, Diabetes and Metabolic Diseases in the Department of Medicine at Sidney Kimmel Medical College of Thomas Jefferson University. He is also Director of the Jefferson Diabetes Center. Dr. Jabbour completed his training in Endocrinology, Diabetes, and Metabolic Diseases at Thomas Jefferson University. He has received many honors and teaching awards. Philadelphia magazine has named him one of their Top Docs every year since 2011, and Castle Connolly has listed him as one of the best endocrinologists in the nation every year since 2012.

A member of numerous professional organizations, including the Endocrine Society, the American Diabetes Association, and the American Association of Clinical Endocrinologists, Dr. Jabbour serves on the editorial boards of numerous journals and chairs the Endocrine Board Review Committee for the Endocrine Society. He has published many articles and chapters on diabetes, metabolic syndrome, and various endocrine topics.

Dr. Jabbour’s main research interest is diabetes. He is involved in many clinical research trials related to new diabetes drugs. He also frequently lectures all over the world on different endocrine topics, mainly diabetes, in the setting of grand rounds, symposia, or other continuing medical education presentations.

Stephen D. Wiviott, MD, FACC
Executive Director, Clinical Trials Office
Partners HealthCare
Senior Investigator
Thrombolysis in Myocardial Infarction (TIMI) Study Group
Cardiovascular Division, Brigham and Women's Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Dr. Stephen Wiviott graduated from the University of Pennsylvania and Harvard Medical School (HMS, Honors). He served as a Medicine Resident and Chief Medical Resident at Brigham and Women’s Hospital (BWH). Following his medical residency training, he served as a Cardiology fellow at Johns Hopkins Hospital. He is Associate Professor of Medicine at HMS, and a Senior Investigator with the TIMI study group. He attends in the Lown Cardiovascular Intensive Care Unit and general Cardiology service at BWH.

As an investigator, Dr. Wiviott has played important roles in the planning, implementation, leadership, and interpretation of multicenter, national, and international clinical trials in acute coronary syndromes including the TRITON-TIMI 38 trial, PRINCIPLE-TIMI 44, and TIMI 38 Coronary Stent Registry. He has also led trials of secondary prevention of cardiovascular disease as global Principal Investigator of DECLARE –TIMI 58 and CAMELLIA –TIMI 61 assessing cardiovascular safety and efficacy of metabolic therapies. Chairman of the TIMI Clinical Events Committee, he is recognized as an expert in event definitions and adjudications. Dr. Wiviott has authored nearly 200 peer-reviewed publications in major medical and cardiovascular journals. He was named in 2014 and 2017 by Thomson Reuters and Clarivate Analytics as one of “The World’s Most Influential Scientific Minds” and in 2016 as a “Highly Cited Researcher,” recognitions inclusive of the top 1% of researchers in Clinical Medicine by citation.

Building on his trials experience, Dr. Wiviott was appointed Executive Director of the Clinical Trials Office (CTO) for Partners HealthCare. The CTO provides contracting, budgeting, and clinical trial management services for Partners hospital investigators and industry sponsors and is tasked with supporting and growing clinical trials research at Partners.

Disclosure of Conflicts of Interest
Global Education Group (Global) requires instructors, planners, managers, and other individuals and their spouses/life partners who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Name of Faculty or Presenter

Reported Financial Relationship

Christopher P. Cannon, MD

Consultant/Independent Contractor:Aegerion Pharmaceuticals, Inc., Alnylam Pharmaceuticals Inc., Amarin Corporation, Amgen Inc., Applied Therapeutics, Inc., Asendia USA, Boehringer-Ingelheim, Bristol-Myers Squibb, Corvidia Therapeutics Inc., HLS Therapeutics Inc., Innovent Biologics, Inc., Janssen Pharmaceuticals, Inc., Kowa
Pharmaceuticals America, Inc., Merck & Co., Inc., Pfizer Inc., sanofi-aventis U.S. LLC; Grant/Research Support: Amgen Inc., Boehringer-Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo Company, Limited, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Pfizer Inc.

Serge A. Jabbour, MD, FACP, FACE

Consultant/Independent Contractor: AstraZeneca; Speakers Bureau:Janssen Pharmaceuticals, Inc.

Stephen D. Wiviott, MD, FACC

Consultant/Independent Contractor:Arena Pharmaceuticals, Inc., AstraZeneca, Aegerion Pharmaceuticals, Inc., Allergan, Inc., Angel Medical Systems, Inc., Boehringer Ingelheim, Boston Clinical Research Institute, Bristol-Myers Squibb Company, Daiichi Sankyo Company, Limited, Eisai Inc., Eli Lilly and Company, ICON plc, Janssen Therapeutics, Lexicon Pharmaceuticals, Inc., Merck & Co., Inc., Servier Pharmaceuticals LLC, St. Jude Medical, Inc., Xoma Biotechnology; Grant/Research Support: Amgen, Arena Pharmaceuticals, Inc.,
AstraZeneca, Bristol-Myers Squibb, Daiichi Sankyo Company, Limited, Eisai Inc., Eli Lilly and Company, Janssen Therapeutics, Merck & Co., Inc., sanofi-aventis U.S. LLC; Other: Spouse is an employee of Merck & Co., Inc.

The following planners and managers reported that neither they nor their spouses/life partners have financial relationships or relationships to products or devices with commercial interests related to the content of this CME activity:

Lindsay Borvansky, Andrea Funk, Liddy Knight, Ashley Cann, Gena Dolson, Celeste Collazo, Jim Kappler, PhD

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global Education Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global and Integritas Communications do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Instructions to Receive Credit
In order to receive credit for this activity, the participant must complete the posttest and program evaluation. Your posttest will automatically be graded. If you successfully complete the posttest (score of 80% or higher), your statement of participation will be made available immediately. Click on the View Statement of Participation link and print the statement for your records. If you receive a score lower than 80%, you will receive a message notifying you that you did not pass the posttest. You will have 2 opportunities to pass the posttest.

For information about the accreditation of this program, please contact Global at 303-395-1782 or

Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.